Summit Medical Group to Implement Altura’s Novel HCP Studies™ Mobile Platform to Support Expanding Patient Access to Clinical Studies
MISSION VIEJO, Calif. and BERKELEY HEIGHTS, N.J., June 13, 2018 (GLOBE NEWSWIRE) -- Altura, the pioneer in expanding participation in health-related studies by streamlining connections between patients, healthcare providers (HCPs) and healthcare organizations, today announced that Summit Medical Group has agreed to implement the company’s HCP Studies™ mobile platform across its growing medical practice. Summit Medical Group is New Jersey’s largest physician-owned medical group with more than 800 HCPs representing over 80 medical specialties. As part of the agreement, the group will utilize Altura’s HCP Studies™ as a conduit to inform and encourage participation in its expanding clinical research efforts throughout the group’s ecosystem of HCPs.
A central component of Altura’s Study Engagement Platform™, HCP Studies™ is a user-friendly communication and processing mobile application/portal platform that aims to simplify efforts to identify and access available clinical studies for HCPs. The current lack of such a platform within the clinical study industry adds an unnecessary layer of difficulty for engaging HCPs and patients in the clinical trial process. By offering the transparency and access to information that HCPs desire, HCP Studies™ is designed to address the chronic issue of suboptimal clinical study enrollment.
“We are pleased to add Summit Medical Group to the growing list of leading medical groups and health systems that are utilizing HCP Studies™ to bolster their internal clinical research efforts,” said Pete Fronte, president and chief executive officer of Altura. “HCP Studies™ is specifically designed to assist in establishing simple and efficient connections between study sites, HCPs and patients. By streamlining these connections, while also providing easy access to relevant study details, our platform aims to significantly expand the number of patients and HCPs participating in clinical studies of all types.”
Summit Medical Group offers novel treatment options to patients through its Clinical Trials Program, which is led by a Research Review Committee, and comprised of Summit Medical Group physicians and staff, who manage all clinical trials, determine the scientific/ethical merits, and identify the potential impact of clinical research on patients. Using Altura’s HCP Studies platform, Summit Medical Group has active clinical trials open for enrollment in a broad range of disease states, including Medical Oncology, Rheumatology, Allergy/Immunology, and Neurology. Details and enrollment information can be found on the Clinical Research section of Summit Medical Group’s website. Open oncology clinical trials in Breast, Gastric, Gynecologic, Hematologic and Lung disease states are as follows.
-- Acute Myeloid Leukemia -- Essential Thrombocytopenia -- Myelofibrosis -- Lymphoma: Diffuse Large B Cell -- Hodgkin Disease Observational -- Chronic Lymphocytic Leukemia -- Non-Small Cell Lung -- Breast Cancer: Metastatic, Early Stage and Adjuvant Radiation -- Endometroid Ovarian, Fallopian Tube, or Primary -- Small-Cell Lung -- Metastatic Pancreatic Cancer, 2nd Line -- Colorectal: Previously treated Metastatic Colorectal Cancer -- Cholangiocarcinoma: Relapsed Cholangiocarcinoma with FGFR translocation
“Conducting cutting-edge medical research, including clinical trials represents an important component of Summit Medical Group’s focus on comprehensive, patient-centered care. With more than 800 HCPs overseeing the care of over half a million active patients, we have broad-ranging capabilities for assisting in the advancement of medical research,” said Gary Pien, MD, medical director of research and clinical trials. “By continuing to build a culture of clinical research, and increasing visibility of our studies among our ever-growing providers, we expect to drive a meaningful increase in participation of our HCPs and patients in a wide range of health studies and clinical trials to advance medicine.”
About Summit Medical GroupRecognized as New Jersey’s premier multispecialty medical group, Summit Medical Group has more than 80 locations in seven northern New Jersey counties. Summit Medical Group’s 800+ practitioners cover more than 80 medical specialties and services, with a focus on delivering patient-centered and coordinated care. Summit Medical Group’s unique care model recently expanded nationally with the founding of Summit Medical Group Oregon – BMC Total Care and Summit Medical Group Arizona. Additionally, Summit Medical Group is the only healthcare provider in northern New Jersey to offer patients access to the world-renowned MD Anderson Cancer Network® through Summit Medical Group MD Anderson Cancer Center. For more information, visit www.summitmedicalgroup.com.
About AlturaBuilt on an 18-year history of successfully connecting point-of-care healthcare providers (HCPs) with relevant medical studies, Altura is the pioneer in expanding patient, HCP and healthcare organization participation in health-related studies (e.g. clinical trials, outcome studies). Altura’s Study Engagement Platform ™ is a proven, HIPAA-compliant and comprehensive method for engaging patients and HCPs and includes their mobile application/portal, HCP Studies™. Altura supports healthcare organizations, research centers and study sponsors (e.g. pharmaceutical, biotechnology and medical device companies). For more information on Altura and its HCP Studies™ mobile platform, please visit www.alturastudies.com.
Contact Information: FOR ALTURA Media and Professional Relations email@example.com
FOR SUMMIT MEDICAL GROUPJoy Lee-CalioDirector, PR firstname.lastname@example.org (908) 977-9502